Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients

Bone Marrow Transplantation volume 27, pages 349–354 (2001)Cite this article

Abstract

We compared fractionated total body irradiation (12 Gy)/cyclophosphamide (120 mg/kg) with busulfan (16 mg/kg)/cyclophosphamide (120 mg/kg) as preparative therapy in unrelated donor stem cell transplantation of CML patients. Fifty patients with CML (1.CP = 46; aP = 4) and a median age of 36 years (range 16–52) were enrolled in this sequential trial between 1994 and 1999. In both groups patients were well balanced with respect to age, disease status, stem cell source and CMV status. All patients received standard doses of cyclosporin A, methotrexate and anti-thymocyte globulin (ATG) as GVHD prophylaxis. No graft failures occurred in either group. The median day of leukocyte engraftment was earlier in the Bu/Cy than in the TBI/Cy group (day 15 vs 17; P = 0.006). The incidence of grade II–IV GVHD was 40% in the TBI/Cy and 36% in the Bu/Cy group, whereas severe grade III/IV GVHD was only observed in 12% of patients in both groups. The incidence of chronic GVHD (limited and extensive) at 1 year was higher in the Bu/Cy arm (65% vs 30%; P = 0.02). More toxicity grade I/II of the liver (88% vs 44%; P = 0.002) and more hemorrhagic cystitis (32% vs 8%; P = 0.02) were observed in the Bu/Cy regimen. Seven relapses in the TBI and no relapse in the Bu/Cy group were observed after a median follow-up of 44 and 15 months, respectively. The estimated 3 year OS and DFS was 72% (95% CI: 55–98%) and 58% (95% CI: 39–77%) in the TBI and 70% (95% CI: 51–89%) for DFS and OS in the Bu/Cy group. We conclude that the anti-leukemic effect of the Bu/Cy regimen seems to be at least as effective as the TBI/Cy combination in unrelated stem cell transplantation of CML patients, with no graft failures, but that it correlates with a higher incidence of liver toxicity, hemorrhagic cystitis and chronic GVHD. Longer follow-up is necessary to determine the late relapse rate and late toxicity. Bone Marrow Transplantation (2001) 27, 349–354.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Marks D, Cullis J, Ward K et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia using sibling and volunteer unrelated donors: a comparison of complications in the first 2 years Ann Intern Med 1993 19: 207–214

    Article  Google Scholar 

  2. McGlave P, Bartsch G, Anasetti C et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: Initial experience of the National Marrow Donor Program Blood 1993 81: 543–550

    CAS  PubMed  Google Scholar 

  3. Kernan NA, Bartsch G, Ash RC et al. Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program New Engl J Med 1993 328: 593–602

    Article  CAS  PubMed  Google Scholar 

  4. Hansen JA, Gooley TA, Martin PJ et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia New Engl J Med 1998 338: 962–968

    Article  CAS  PubMed  Google Scholar 

  5. Spencer A, Szydia RM, Brookes PA et al. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient Blood 1995 86: 3590–3597

    CAS  PubMed  Google Scholar 

  6. Devergie A, Blaise D, Attal M et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-Total-body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft Blood 1995 85: 2263–2268

    CAS  PubMed  Google Scholar 

  7. Clift RA, Buckner CD, Thomas ED et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide Blood 1994 84: 2036–2043

    CAS  PubMed  Google Scholar 

  8. Mehta J, Powles RL, Mitchell P et al. Graft failure after bone marrow transplantation from unrelated donors using busulfan and cyclophosphamide for conditioning Bone Marrow Transplant 1994 13: 583–587

    CAS  PubMed  Google Scholar 

  9. Klein JL, Avalos BR, Belt P et al. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy Bone Marrow Transplant 1996 17: 479–483

    CAS  PubMed  Google Scholar 

  10. Topolsky D, Crilley P, Styler MJ et al. Unrelated donor bone marrow transplantation without T cell depletion using a chemotherapy only conditioning regimen. Low incidence of failed engraftment and severe acute GVHD Bone Marrow Transplant 1996 17: 549–554

    CAS  PubMed  Google Scholar 

  11. Bertz H, Potthoff K, Mertelsmann R, Finke J . Busulfan/cyclophosphamide in volunteers unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity Bone Marrow Transplant 1997 19: 1169–1173

    Article  CAS  PubMed  Google Scholar 

  12. Przepiorka KM, Weisdorf D, Martin P . 1994 Consensus Conference on acute GVHD-grading Bone Marrow Transplant 1995 15: 825–828

    CAS  PubMed  Google Scholar 

  13. Bearman SI, Appelbaum FR, Buckner CD et al. Regimen related toxicity in patients undergoing bone marrow transplantation J Clin Oncol 1988 6: 1562–1568

    Article  CAS  PubMed  Google Scholar 

  14. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients Ann Intern Med 1993 118: 255–267

    Article  CAS  PubMed  Google Scholar 

  15. Beatty PG, Ash R, Hows JM, McGlave PB . The use of unrelated bone marrow donors in the treatment of chronic myelogenous leukemia: experience of four centers Bone Marrow Transplant 1989 4: 287–290

    CAS  PubMed  Google Scholar 

  16. Santos GW, Tutschka Pj, Brookmeyer R et al. Marrow transplantation for acute non-lymphomic leukemia after treatment with busulfan and cyclophosphamide New Engl J Med 1983 309: 1347–1353

    Article  CAS  PubMed  Google Scholar 

  17. Tutschka PJ, Copelan EA, Klein, JA et al. Bone marrow transplantation for leukemia following new busulfan and cyclophosphamide regime Blood 1987 70: 1382–1388

    CAS  PubMed  Google Scholar 

  18. Sahebi F, Copelan E, Crilley P et al. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide for preparative regimen Bone Marrow Transplant 1996 17: 329–333

    Google Scholar 

  19. Ringden O, Ruutu T, Remberger M et al . for the Nordic Bone Marrow Transplantation Group A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantion Group Blood 1994 83: 2723–2730

    CAS  PubMed  Google Scholar 

  20. Andersson BS, Giralt S, Tran H et al. I.V. busulfan, cytoxan and allogeneic hematopoietic stem cell transplantation for advanced hematological malignancies Bone Marrow Transplantat 1999 23: (Suppl. 1) 223

    Google Scholar 

  21. Gratwohl A, Hermans J, Niederwieser D et al . for the Chronic Leukemia Working Party of the EBMT Bone marrow transplantation for chronic myeloid leukemia: long terms results Bone Marrow Transplant 1993 12: 509–516

    CAS  PubMed  Google Scholar 

  22. Devergie A, Apperley JF, Labopin M et al for the Chronic Leukemia Working Party of the European Group of Blood and Marrow Transplantation . European results of matched unrelated bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching Bone Marrow Transplant 1997 20: 11–19

    Article  CAS  PubMed  Google Scholar 

  23. Sierra J, Storer B, Hansen J et al. Transplantation of marrow cells from unrelated donors for treatment of high risk acute leukemia: the effect of leukemia burden, donor HLA-matching and marrow cell dose Blood 1997 89: 4226–4235

    CAS  PubMed  Google Scholar 

  24. Kröger N, Zabelina T, Krüger W et al. Anti-human T-lymphocyte globulin (ATG) as part of the conditioning regimen in unrelated bone marrow transplantation of patients with CML in chronic or accelerated phase Blood 1998 92: (Suppl. 1) 578

    Google Scholar 

  25. Zander AR, Zabelina T, Löliger C et al. Bone marrow transplantation from mismatched unrelated donors Bone Marrow Transplant 2000 25: (Suppl. 1) 36

    Google Scholar 

  26. Zander AR, Zabelina T, Kröger N et al. Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow Bone Marrow Transplant 1999 23: 889–893

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the staff of the BMT unit for providing excellent care of our patients and the medical technicians for their excellent work in the BMT laboratory.

Author information

Authors and Affiliations

  1. Bone Marrow Transplantation, University-Hospital, Hamburg, Germany

    N Kröger, W Krüger, H Renges, N Stute, H Kabisch, N Jaburg & AR Zander

  2. Pavlow University, St Petersburg, Russia

    T Zabelina

  3. Department of Transfusion Medicine, University-Hospital Hamburg, Germany

    C Löliger

  4. Department of Radiation Therapy, University-Hospital Hamburg, Germany

    A Krüll

Authors
  1. N Kröger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Zabelina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W Krüger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H Renges
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N Stute
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H Kabisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N Jaburg
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C Löliger
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A Krüll
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. AR Zander
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kröger, N., Zabelina, T., Krüger, W. et al. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients. Bone Marrow Transplant 27, 349–354 (2001). https://doi.org/10.1038/sj.bmt.1702802

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702802

Keywords

This article is cited by

Search

Advanced search

Quick links